Rezultati - Choi, Yoo‐Duk
- Showing 1 - 20 results of 94
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2 od Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul
Izdano 2019Text -
18
-
19
-
20
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1 od Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul
Izdano 2021Text